Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02729389
Other study ID # IRB201600361
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2016
Est. completion date July 7, 2018

Study information

Verified date September 2019
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to investigate how social standing in a game of Monopoly may influence behavior.


Description:

Participants will be asked to fill out questionnaires/surveys and health measures will be collected throughout the study visit. These health measures will include: blood pressure, heart rate, height/weight, waist circumference, percent body fat, resting metabolic rate, and salivary cortisol. Breakfast will be provided and then a 40-minute game of Monopoly™ will be played, and lunch will be provided after the game. Participants will be given an accelerometer to measure movements, and a food diary to be used for a 24-hour period. Once the 24-hour monitoring period has been completed, the participants will be finished with the study activities. The accelerometer and food diary will be returned by either bringing them to the investigators or mailing the items back to the investigators.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date July 7, 2018
Est. primary completion date July 7, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 21 Years
Eligibility Inclusion Criteria:

- Hispanic American adolescents born in the United States

- Have played Monopoly before

Exclusion Criteria:

- Clinical depression

- A diagnosis of cardiovascular disease (active or within the past 6 months), cancer (active or within the past 2 years, except non-melanoma skin cancer), diabetes (type 1 or 2), active or chronic infections, gastrointestinal disease, active kidney disease, lung disease, uncontrolled psychiatric disease

- An eating disorder or severely restricted diet

- Use of tobacco products

- Substance abuse disorder

- Take any medications known to affect appetite or body composition

- Participation in any weight-reduction programs, weight-loss diets, or other special diets within the previous 3 months

- Experience of weight loss or gain of 10 pounds or more of body weight in the past 6 months for any reason except post-partum weight loss

- Current/Anticipation of pregnancy during study

- Currently nursing or within 6 weeks of having completed nursing

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High Social Status Condition
Participants will be provided with a high degree of privilege in a game of Monopoly.
Low Social Status Condition
Participants will be provided with a low degree of privilege in a game of Monopoly.

Locations

Country Name City State
United States University of Florida Clinical Translational Science Institute Gainesville Florida

Sponsors (3)

Lead Sponsor Collaborator
University of Florida Brown University, University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Energy balance between the groups at hour 4 and over 24 hours The investigators will assess energy balance using accelerometry, consumption data and resting metabolic rate. Hour 4, After 24 Hours
Secondary Change in blood pressure between the groups at hours 0, 1, 3, 4 Systolic and diastolic blood pressure will be assessed. Hours 0, 1, 3, 4
Secondary Change in heart rate between the groups at hours 0, 1, 3, 4 Heart rate will be captured using a heart rate monitor. Hours 0, 1, 3, 4
Secondary Change in salivary cortisol between the groups at hours 1, 3 Salivary cortisol will be collected and tested to determine objective stress levels. Hours 1, 3
Secondary Change in Visual Analog Scales (VAS) between the groups at hours 0, 1, 3, 4 Scores are from 0 - 100, 0 generally meaning least and 100 generally meaning most. Hours 0, 1, 3, 4
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment